Lv1
30 积分 2025-08-18 加入
Magnetic resonance imaging radiomic phenotypes stratify response and define immune states in very high-risk, nonmuscle-invasive bladder cancer treated with tislelizumab plus nanoparticle albumin-bound paclitaxel
22天前
已完结
HER2-targeted therapies beyond breast cancer — an update
1个月前
已完结
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
4个月前
已完结
Intravesical Disitamab Vedotin (RC48) for HER2‐Expressing High‐Risk Non‐Muscle‐Invasive Bladder Cancer: A Single‐Arm, Dose–Escalation Phase I Trial Study
5个月前
已完结
Efficacy and biomarker analysis of neoadjuvant disitamab vedotin (RC48‐ADC) combined immunotherapy in patients with muscle‐invasive bladder cancer: A multi‐center real‐world study
5个月前
已完结
Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study
5个月前
已完结
Targeting Sialylation Enhances the Therapeutic Efficacy of the Nectin-4-Targeted Antibody-Drug Conjugate Enfortumab Vedotin in Bladder Cancer
7个月前
已完结
Efficacy and Safety of Disitamab Vedotin Combined with Gemcitabine as Neoadjuvant Therapy in Muscle-invasive Bladder Cancer: An Open-label, Multicenter, Single-arm, Phase 2 Trial
7个月前
已完结
Antibody–drug conjugates for non-muscle invasive bladder cancer: current status and future development
7个月前
已完结
HER2 and urothelial carcinoma: current understanding and future directions
8个月前
已完结
皖公网安备34019202002308
